ROS1-dependent cancers — biology, diagnostics and therapeutics
- 5 August 2020
- journal article
- review article
- Published by Springer Science and Business Media LLC in Nature Reviews Clinical Oncology
- Vol. 18 (1), 35-55
- https://doi.org/10.1038/s41571-020-0408-9
Abstract
The proto-oncogene ROS1 encodes a receptor tyrosine kinase with an unknown physiological role in humans. Somatic chromosomal fusions involving ROS1 produce chimeric oncoproteins that drive a diverse range of cancers in adult and paediatric patients. ROS1-directed tyrosine kinase inhibitors (TKIs) are therapeutically active against these cancers, although only early-generation multikinase inhibitors have been granted regulatory approval, specifically for the treatment of ROS1 fusion-positive non-small-cell lung cancers; histology-agnostic approvals have yet to be granted. Intrinsic or extrinsic mechanisms of resistance to ROS1 TKIs can emerge in patients. Potential factors that influence resistance acquisition include the subcellular localization of the particular ROS1 oncoprotein and the TKI properties such as the preferential kinase conformation engaged and the spectrum of targets beyond ROS1. Importantly, the polyclonal nature of resistance remains underexplored. Higher-affinity next-generation ROS1 TKIs developed to have improved intracranial activity and to mitigate ROS1-intrinsic resistance mechanisms have demonstrated clinical efficacy in these regards, thus highlighting the utility of sequential ROS1 TKI therapy. Selective ROS1 inhibitors have yet to be developed, and thus the specific adverse effects of ROS1 inhibition cannot be deconvoluted from the toxicity profiles of the available multikinase inhibitors. Herein, we discuss the non-malignant and malignant biology of ROS1, the diagnostic challenges that ROS1 fusions present and the strategies to target ROS1 fusion proteins in both treatment-naive and acquired-resistance settings.Keywords
This publication has 193 references indexed in Scilit:
- Exploration of the gene fusion landscape of glioblastoma using transcriptome sequencing and copy number dataBMC Genomics, 2013
- The frequency and impact of ROS1 rearrangement on clinical outcomes in never smokers with lung adenocarcinomaAnnals of Oncology, 2013
- Mouse Model for ROS1-Rearranged Lung CancerPLOS ONE, 2013
- The transcriptional landscape and mutational profile of lung adenocarcinomaGenome Research, 2012
- The cBio Cancer Genomics Portal: An Open Platform for Exploring Multidimensional Cancer Genomics DataCancer Discovery, 2012
- ROS1 Rearrangements Define a Unique Molecular Class of Lung CancersJournal of Clinical Oncology, 2012
- Insights into ALK-Driven Cancers Revealed through Development of Novel ALK Tyrosine Kinase InhibitorsCancer Research, 2011
- Survey of Tyrosine Kinase Signaling Reveals ROS Kinase Fusions in Human CholangiocarcinomaPLOS ONE, 2011
- The multifaceted roles of the receptor tyrosine kinase ROS in development and cancerBiochimica et Biophysica Acta (BBA) - Reviews on Cancer, 2009
- Comprehensive genomic characterization defines human glioblastoma genes and core pathwaysNature, 2008